Alexander Lewandrowski

Mr. Alexander Lewandrowski


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Kai-Uwe LewandrowskiKai-Uwe Lewandrowski
Kai-Uwe Lewandrowski
KBKenneth Blum
Kenneth Blum
Alireza SharafshahAlireza Sharafshah
Alireza Sharafshah
KTKyriaki Z. Thanos
Kyriaki Z. Thanos
Panayotis ThanosPanayotis Thanos
Panayotis Thanos
SSSergio Luis Schmidt
Sergio Luis Schmidt
Background: In the United States, approximately 1 in 5 children experience comorbidities with mental illness, including depression and anxiety, which lead to poor general health outcomes. Adolescents with substance use disorders exhibit high rates of co-occurring mental illness, with over 60% meeting diagnostic criteria for another psychiatric condition in community-based treatment programs. Comorbidities are influenced by both genetic (DNA antecedents) and environmental (epigenetic) factors. Given the significant impact of psychiatric comorbidities on individuals’ lives, this study aims to uncover common mechanisms through a Genome-Wide Association Study (GWAS) meta-meta-analysis. Methods: GWAS datasets were obtained for each comorbid phenotype, followed by a GWAS meta-meta-analysis using a significance threshold of p < 5E−8 to validate the rationale behind combining all GWAS phenotypes. The combined and refined dataset was subjected to bioinformatic analyses, including Protein–Protein Interactions and Systems Biology. Pharmacogenomics (PGx) annotations for all potential genes with at least one PGx were tested, and the genes identified were combined with the Genetic Addiction Risk Severity (GARS) test, which included 10 genes and eleven Single Nucleotide Polymorphisms (SNPs). The STRING-MODEL was employed to discover novel networks and Protein–Drug interactions. Results: Autism Spectrum Disorder (ASD) was identified as the top manifestation derived from the known comorbid interaction of anxiety, depression, and attention deficit hyperactivity disorder (ADHD). The STRING-MODEL and Protein–Drug interaction analysis revealed a novel network associated with these psychiatric comorbidities. The findings suggest that these interactions are linked to the need to induce “dopamine homeostasis” as a therapeutic outcome. Conclusions: This study provides a reliable genetic and epigenetic map that could assist healthcare professionals in the therapeutic care of patients presenting with multiple psychiatric manifestations, including anxiety, depression, and ADHD. The results highlight the importance of targeting dopamine homeostasis in managing ASD linked to these comorbidities. These insights may guide future pharmacogenomic interventions to improve clinical outcomes in affected individuals.

3 July 2025 in Gene & Protein in Disease
Verified
Journal Article
Open access
PDF file
KBKenneth Blum
Kenneth Blum
Alireza SharafshahAlireza Sharafshah
Alireza Sharafshah
KLKai-Uwe Lewandrowski
Kai-Uwe Lewandrowski
SSSérgio Luís Schmidt
Sérgio Luís Schmidt
RFRossano Kepler Alvim Fiorelli
Rossano Kepler Alvim Fiorelli
Rajendra D. BadgaiyanRajendra D. Badgaiyan
Rajendra D. Badgaiyan
The convergence of neurogenetics, epigenetics, and functional neuroimaging presented in this article marks a critical inflection point in our understanding and management of reward deficiency syndrome (RDS) and its behavioral expressions across pain and addiction medicine. The evidence for a hypodopaminergic state, now supported by decades of molecular, clinical, and imaging data, has culminated in the formulation of a scientifically grounded, personalized, and preventative paradigm— anchored by the concept of early genetic testing to provide risk information linked to “prediction” predominantly due to dopaminergic dysfunction. From a translational standpoint, this model offers more than a framework for understanding neurobiological vulnerability; it provides a practical roadmap for early identification of “pre-addiction,” informed opioid prescribing, relapse prevention, and long-term neurorecovery. The coupling of Genetic Addiction Risk Severity (GARS) with dopaminergic modulation—via safe, non-addictive interventions—could redefine standard treatment algorithms not only for substance use disorders but also for a broader spectrum of compulsive and comorbid behaviors. This study by members of the RDS Consortium explores the concept of “pre-addiction” within addiction biology through a comprehensive in silico analysis of 88,788,381 genome-wide association study-based samples from 1,373 studies, identifying 18 significant genes (e.g., APOE with p=1.0E-126) linked to opioids, pain, aging, and apoptosis pathways. It aims to correlate these genes with GARS, which includes 10 specific genes, and highlights the most connected genes, such as MAOA, COMT, APOE, and SLC4A6, through a STRING model. The analysis expanded to 27 unique genes, emphasizing significant interactions with hsa-miR-16-5p and hsa-miR-24-3p, especially SLC6A4. Through pharmacogenomics mining, 1,173 variant annotations were identified for these genes. Enrichment analysis and meta-analysis further validated these findings, illustrating the pivotal role of dopaminergic pathways in connecting addictive behaviors and depressive symptoms. The results support the conceptualization of RDS as the fundamental preaddiction phenotype, with pain, opioid dependence, aging, and apoptosis as critical endophenotypes.

24 July 2025 in Academia Molecular Biology and Genomics
Verified
Journal Article
Open access
PDF file
Edward Justin ModestinoEdward Justin Modestino
Edward Justin Modestino
Alireza SharafshahAlireza Sharafshah
Alireza Sharafshah
KLKai Uwe Lewandrowski
Kai Uwe Lewandrowski
ECElizabeth Carey
Elizabeth Carey
KMKavya Mohankumar
Kavya Mohankumar
KBKenneth Blum
Kenneth Blum
We previously theorized that Attention-Deficit Hyperactivity Disorder (ADHD) may increase susceptibility to narcolepsy and hypersomnia, potentially sharing genomic and pathophysiological features with addictive behaviours linked to Reward Deficiency Syndrome (RDS). We further suggested that the emergence of narcolepsy in individuals with underlying ADHD or RDS may place additional stress on the dopaminergic reward system. To explore this, we conducted comprehensive data mining using GWAS catalog databases focused on ADHD and narcolepsy, identifying three relevant datasets. These were individually analyzed in GWAS meta-analyses, followed by a combined GWAS meta-meta-analysis. From this, we derived a Primary Gene List (PGL) of 512 genes and a Secondary Gene List (SGL) of 42 genes, which were further examined through in-depth silico, systems biology, and pharmacogenomic (PGx) approaches. Our findings revealed a fully connected protein–protein interaction (PPI) network between ADHD and narcolepsy, with FOXP2 and RBFOX1 emerging as shared genes. We also identified schizophrenia as a potential endophenotype linking ADHD and narcolepsy. PGx analysis revealed pharmacogenomic relevance for seven genes from the SGL. To further investigate PGx–PPI relationships, we incorporated ten GARS family genes along with eight identified pharmacogenes in PGx-PPIs, and included FOXP2, RBFOX1, and GRIN2A, despite the absence of PGx data for the latter three. This analysis highlighted DRD2 and NRXN1 as central components of the dopaminergic [Genetic Addiction Risk Severity (GARS)] pathway, forming critical connections in the ADHD–schizophrenia–narcolepsy axis. These results support our initial hypothesis of a shared genetic basis between ADHD and narcolepsy. Additionally, we identified potentially overlapping genes with schizophrenia and highlighted dopaminergic regulatory variants of FOXP2, RBFOX1, and GRIN2A as promising diagnostic markers and therapeutic targets for future research.

29 November 2025 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
Alireza SharafshahAlireza Sharafshah
Alireza Sharafshah
KBKenneth Blum
Kenneth Blum
Kai-Uwe LewandrowskiKai-Uwe Lewandrowski
Kai-Uwe Lewandrowski
Igor ElmanIgor Elman
Igor Elman
BFBrian Fuehrlein
Brian Fuehrlein
MGMark Gold
Mark Gold
Background: There are important gaps in describing the associations between variants found by GWAS and various phenotypes. Prior reports suggest that SNPs in regulatory regions should be further investigated to uncover these associations. Thus, this study involved a novel approach, along with Pharmacoepigenomics, prompting a new coined term “CpG-PGx SNP”. Methods: The rationale behind our analysis strategy was based on the impact of SNPs playing dual roles both in the CpG site disruption/formation and having PGx associations. Thus, we employed GeneCards (relevance score), PharmGKB (significant p-value), and GWAS catalog data for each gene (p < 5 × 10−8). Following the obtainment of the 25 best-scored genes of four major epigenetic processes (methylation, demethylation, acetylation, and deacetylation), we generated two lists of candidate genes, including potential CpG-PGx SNPs and possible CpG-PGx SNPs. Results: Among 2900 significant PGx annotations, we found 99 potential CpG-PGx SNPs related to 16 genes. CYP2B6, CYP2C19, CYP2D6, and COMT genes were the top genes. Additionally, we found 1230 significant GWAS-based SNPs, among them 329 CpG-SNPs related to 48 genes with at least one CpG site disruption/formation. The top gene with the highest CpG-SNPs was TET2, followed by JMJD1C and HDAC9. Importantly, we detected some synonymous variants in the Epigenetically Modifiable Accessible Region (EMAR), which can provide insights into undiscovered roles of these SNPs. We identified 173 CpG-Disruptive SNPs, 155 CpG-Forming SNPs, and just 1 CpG SNP with both impacts. Conclusions: In conclusion, here we introduce CpG-PGx SNP for the first time and suggest three major genes playing crucial roles in Pharmacoepigenomics (PEpGx), CYP2D6 as the heart of PEpGx, and TET2 with the highest possibility of having CPG-PGx SNPs. We believe that this approach will help the scientific community to utilize “CpG-PGx SNP” to unravel complex disease-driven genetic and epigenetic interactions, yielding therapeutic opportunities.

24 October 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
YMYatharth Mahajan
Yatharth Mahajan
SMShaurya Mahajan
Shaurya Mahajan
Alireza SharafshahAlireza Sharafshah
Alireza Sharafshah
KSKeerthy Sunder
Keerthy Sunder
Kai-Uwe LewandrowskiKai-Uwe Lewandrowski
Kai-Uwe Lewandrowski
KBKenneth Blum
Kenneth Blum
Background: GLP‑1 receptor agonists (GLP‑1RAs) are effective for type 2 diabetes and obesity and engage central stress and reward pathways (HPA axis; mesolimbic dopamine). Psychiatric signals have been reported in some settings. Objective :To narratively synthesize evidence on neuropsychiatric effects of GLP‑1RAs—mood, anxiety, suicidality, reward processing, substance use, and migraine—and to consider genetic/epigenetic moderators (e.g., hypodopaminergia/reward deficiency syndrome).Evidence: Mechanistic and imaging studies demonstrate GLP‑1 engagement of HPA and reward circuitry; animal work suggests acute anxiogenic responses with mixed chronic effects. Pharmacovigilance datasets (FAERS/EudraVigilance) show signals for headache, dizziness, sensory changes, and less consistently for depression/anxiety/suicidality; such data are hypothesis‑generating and not causal. Clinical trials and meta‑analyses report heterogeneous outcomes, including small antidepressant effects in some T2DM cohorts. Conclusions: Neuropsychiatric outcomes with GLP‑1RAs appear context‑dependent. Individuals with hypodopaminergic biology may be vulnerable to reward blunting/anxiety, whereas others may experience mood benefits. A pragmatic approach is screen–stratify–monitor, with slow titration and prompt adjustment if psychiatric signals emerge. Prospective, genotype‑informed studies are needed to identify who benefits or is harmed and why.

4 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Alireza SharafshahAlireza Sharafshah
Alireza Sharafshah
KBKenneth Blum
Kenneth Blum
KMKavya Mohankumar
Kavya Mohankumar
Milan T. MakaleMilan T. Makale
Milan T. Makale
ABAbdalla Bowirrat
Abdalla Bowirrat
Rajendra D. BadgaiyanRajendra D. Badgaiyan
Rajendra D. Badgaiyan
Autism Spectrum Disorder (ASD) is a complex syndrome with a plethora of clinical manifestations. Although such variability may be attributable to diverse genetic and epigenetic factors, mesolimbic dopaminergic reward pathways are consistently implicated in the illness’ course and neuropathobiology pointing to a need in an updated perspective on such a potential overlap area. To that end, we introduce a structured framework dissecting ASD's pathophysiology into stages while emphasizing the involvement of the classical reward structures. Through data mining of Genome-Wide Association Studies (GWAS) and in silico analyses, we uncovered genetic and epigenetic markers pointing to Reward Deficiency Syn-drome (RDS) component of ASD. We employ innovative approaches, including protein-protein interactions, gene regulatory networks, and systems biology analyses, to identify pathways and ASD gene ontologies. The multi-omics analysis integrates findings across genomics, proteomics, metabolomics, and phenomics, reinforcing the concept of ASD as an endophenotype of RDS. This comprehensive approach offers new insights into the genetic architecture and molecular mechanisms of ASD, paving the way for personalized medicine strategies thus yielding novel therapeutic interventions.